Dose-Ranging Study of the Bimatoprost Ocular Insert

Completed · Phase 2 · Has a placebo group

Conditions studied: Primary Open-Angle Glaucoma, Ocular Hypertension

In brief

The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with Open-Angle Glaucoma or Ocular Hypertension. This study evaluated the safety and efficacy of two different doses of the Bimatoprost Ocular Insert, compared to an active control arm with timolol ophthalmic solution (0.5%).

Key facts

Study ID

NCT02358369

Run by

ForSight Vision5, Inc.

People needed

156

Starts

2015-01-19

Expected to finish

2015-10-07

Last updated by the study team

2020-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Vold Vision — Fayetteville, Arkansas, United States
• Sall Medical Research Center — Artesia, California, United States
• Eye Research Foundation — Newport Beach, California, United States
• Clayton Eye Center — Morrow, Georgia, United States
• Mundorf Eye Center — Charlotte, North Carolina, United States
• Cornerstone Health Care — High Point, North Carolina, United States
• Apex Eye — Madeira, Ohio, United States
• University of Eye Specialists — Maryville, Tennessee, United States
• Total Eye Care — Memphis, Tennessee, United States
• R&R Eye Research, LLC — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.